Navigation Links
Global Automated And Rapid Microbiological Tests Industry
Date:10/25/2011

NEW YORK, Oct. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Automated And Rapid Microbiological Tests Industry

http://www.reportlinker.com/p092467/Global-Automated-And-Rapid-Microbiological-Tests-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

This report analyzes the worldwide markets for Automated and Rapid Microbiological Tests in US$ Million by the following end-use segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, & Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 125 companies including many key and niche players such as Abbott Laboratories, Abbott Diagnostics, Alere Inc., Becton Dickinson and Company, bioMerieux SA, bioMerieux, Inc., Bio-Rad Laboratories, Inc., Cellabs Pty Ltd, Celsis International Plc., Coris BioConcept, F. Hoffmann-La Roche Ltd., Gen-Probe Inc., Genzyme Diagnostics, MedMira Inc., Meridian Biosciences, Inc., Orasure Technologies, Inc., Orion Diagnostica Oy, Quidel Corporation, Siemens Healthcare Diagnostics, Inc., Thermo Fisher Scientific, Inc., Remel, Inc., and Oxoid Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

AUTOMATED AND RAPID MICROBIOLOGICAL TESTS MCP-1093

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

Clinical Applications 4

Automated Identification and Susceptibility Systems 4

Automated Blood Culture Systems 4

Automated Tuberculosis Systems 5

Streptococcal Infection Rapid Tests 5

GC/Chlamydia Rapid Tests 5

Other Automated & Rapid Microbiological Tests 5

Non-Clinical Applications 5

2. INDUSTRY OVERVIEW 6

Outlook 6

Evolutionary Battle Against Bugs Drives Market Future 6

Automated Microbiological Tests: A Pesky Gray Area in the

Clinical Diagnostics Market 6

Traditional Rapid Microbiological Tests Destined to Go Out

With the Old 7

A Current & Future Analysis 7

Segmental Perspective 8

Clinical Applications 8

Non-Clinical Applications 8

Macro: The Big Picture 8

Deciding the Market's Future 9

A Holistic Peek into a Few Noteworthy Trends 9

Biotechnology & Rapid Microbial Tests 10

Automated & Rapid Microbiological Tests: "Current Market Stance" 11

A Business Case for Automated & Rapid Microbiological Testing 11

Near Patient Testing: An Offshoot of Rapid Microbiological Tests 11

Pros & Cons of Near Patient Testing 12

Role of Near Patient Testing in Reducing Antibiotic

Resistance in Humans 12

The Pre/Post Microbial Rapid Testing Era: A Review 13

Market Structure 13

Competitive Setup of the Diverse Automated & Rapid

Microbiology Products Market 13

Competitive Landscape 14

Table 1: World Market for Microorganism Identification and

Resistance Tests by Leading Players (2008): Market Share

Breakdown of Value Share for BioMerieux; Becton, Dickinson

and Co; Siemens AG; and Others (includes corresponding

Graph/Chart) 14

Table 2: World In-Vitro Diagnostics (IVD) Market by Leading

Players (2008): Market Share Breakdown for Roche, Siemens,

Abbott Diagnostics, Becton Dickinson, Beckman Coulter, OCD

, BioMerieux, Sysmex, Others (includes corresponding

Graph/Chart) 15

Table 3: World Blood Screening Market by Leading Players

(2008): Market Share Breakdown for Gen-Probe/Novartis,

Roche, Homebrew, and Others (includes corresponding

Graph/Chart) 15

3. TRENDS & ISSUES 16

Advancements in Molecular Diagnostics - A Boon or a Threat 16

Leading Companies in Molecular Diagnostics Market 16

Antibiotic Resistant Bacteria Throws the Spotlight On

Microbial Testing 16

Instant Detection of Pathogens - A New Epoch in the Fight for

Survival 17

Lower Cost Rapid Tests Built on Multiple Sampling Modalities -

Gaining Momentum 17

"Time Constraints?" - Rapid Tests to the Rescue 17

Rapid HIV Tests: A New Age Diagnostic Weapon Against the

Killer Disease 18

Accuracy/Reliability of Home HIV Testing: A Bone of Contention 18

Development of Near Patient Test Kits: A Market Driven Phenomenon 19

Near Patient Test Kits: A Rumination of Possibilities 19

Automated Blood Culture Systems: A Winning Edge in the Fight

Against Bacteremia 20

Leading Food Processors Resort to Rapid Microbiological Testing 20

Impact of Food Scares on Rapid Microbiological Tests Market 21

Demand for Microbiological Tests & Level of QC in the Food

Industry 22

Rapid Tests Creating Brighter Avenues in Food Microbiology

Testing Market 23

Dire Need to Nip Operating Costs Throws the Spotlight on Rapid

Tests 23

Key Advantages/Benefits of Rapid Microbiological Tests on Food 24

Food Packages of the Future Ingrained with Microbial Alert

Systems 24

Technology Innovations in Rapid Food Microbial Testing: A

Historic Brief 24

Obtaining Regulatory Approval - A Major Non-Technical Hindrance 25

4. FACTORS INFLUENCING THE MARKET 26

Continuing Biological Warfare with Pathogens Sparks Market Growth 26

Innovative Products - A Key Growth Strategy 26

Other Market Drivers in a Capsule 26

Low Turnaround Times Skyrocket Demand 26

Greater Patient Awareness 27

Rising Incidence of STDs Kindles Universal Market Acceptance 27

Ultra-Rapid HIV-Screening Tests- A Strong Fight against HIV-

Epidemic 27

Validation of Rapid Microbiological Tests: An Imperative

Prerequisite 27

Non-Conformance to Testing Requirements: A Weighty Concern 28

Influenza - Boosting Rapid Test Prospects 29

5. PRODUCT/TECHNOLOGY OVERVIEW 30

Automated & Rapid Microbiological Tests: A Definition 30

Benefits of Automated & Rapid Microbiological Tests 30

Classification of Rapid Microbiological Test Methods 31

How Does a Rapid Test Work? 31

Sample Preparation - A Key Procedure 32

Automated Identification and Susceptibility Systems 32

Automated Blood Culture Systems 32

Automated Tuberculosis Systems 33

Microminiaturization of Diagnostic Tests: How Is It Effected? 33

Advantages of Microminiaturisation: 34

Acid-Fast Microscopy - The Forerunner of Rapid Tests 34

Gram's Stain: A Time-Honored & Rapid Method to Detect

Pathogens in Blood 34

Enabling Technologies of Automated & Rapid Microbiological Tests 35

Growth-based Technologies 35

Viability-based Technologies 35

Cellular-Component or Artifact-based Technologies 36

Genomics/ Proteomics 36

Microarrays/Microfluidics 36

DNA Microchips/Probes 37

Polymerase Chain Reaction (PCR) 37

Immunoassay 37

Immunoassay Escalates into Diverse Fields of Diagnostic Testing 38

Nucleic Acid Testing (NAT) 38

Nucleic Acid Probes 39

Signal-Amplified Tests 39

Nucleic Acid Amplification Tests 39

Traditional Methods with Computer-Aided Imaging 40

Combination Methods 40

6. END-USE APPLICATION ANALYSIS 41

Applications in Clinical Investigations 41

STD Rapid Tests 41

GC/Chlamydia Rapid Tests 41

HIV Rapid Tests 42

HIV Facts & Figures 43

Table 4: Global Prevalence of HIV Infection by Region:

2007 & 2008 (includes corresponding Graph/Chart) 43

Table 5: Global HIV Related Deaths by Region: 2007 & 2008

(includes corresponding Graph/Chart) 44

Table 6: Global Distribution of HIV Prevalence, Incidence

and Mortality: 2008 (includes corresponding Graph/Chart) 44

Advantages of Rapid HIV Testing 45

Disadvantages of Rapid HIV Testing 45

Syphilis Rapid Tests 45

Respiratory Rapid Tests 45

RSV/ Influenza Rapid Tests 46

Tuberculosis Rapid Tests 46

Group A beta Hemolytic Streptococcus Rapid Tests 46

Mononucleosis Rapid Tests 47

Streptococcus Rapid Tests 47

Streptococcus A Rapid Tests 47

Streptococcus B Rapid Tests 48

Gastrointestinal Rapid Tests 48

Giardia Lamblia Rapid Tests 48

H. Pylori Rapid Tests 49

Cryptosporidium Rapid Tests 49

C. Difficile Rapid Tests 50

Applications in Non-Clinical Investigations 50

Food/Water Safety Tests 50

Food Safety Testing: A Lucrative Application Area 50

Rapid Microbiological Methods in Pharmaceutical Sector 51

Limitations of RMMs 52

Advantages of RMMs 52

Applications in Pharmaceutical Sector 52

Environmental Tests 53

Other Miscellaneous Applications 53

7. PRODUCT INNOVATIONS/INTRODUCTIONS 54

Alere Rolls Out three Cardiac Testing Solutions 54

Millipore Introduces New Milliflex Quantum Rapid

Microbiological Test Method 54

BD Diagnostics Adds Automated Microbiology Specimen Processor

to its Diagnostic Portfolio 54

Roche Introduces New Automatic Clinical Laboratory System,

Cobas®4800 55

Thermo Fisher Scientific Launches an Automated Photometric Method 55

Thermo Fisher Scientific Introduces Salmonella Rapid Culture

Method 56

BD Receives FDA Clearance for BD ProbeTec Amplified DNA Assays

on BD Viper System 56

Oxoid Introduces Xpect® Flu A&B 56

Oxoid Extends ProSpecT Range 56

Oxoid Launches ELISA Systems Test Kits Range 57

Oxoid Introduces Brilliance VRE Agar and Brilliance ESBL Agar 57

Oxoid Launches RapID Kits 58

Inverness Medical Innovations Introduces C. DIFF QUIK CHEK

COMPLETETM Rapid Test 58

Celsis International Launches Celsis ReACTTM 59

Roche Diagnostics Introduces LightCycler® Mycobacterium

Detection Kit 60

bioMerieux Introduces NucliSENS EasyQ® HIV-1 v2.0 60

Celsis International Unveils RapiScreenTM Beverage 61

Siemens Launches MicroScan Synergies plus® gram-positive ID/

MIC and MIC Combination Panels 61

Oxoid Introduces IDEIATM Norovirus 61

Oxoid Introduces Salmonella PrecisTM Process 62

Remel Offers FDA Approved RPMI 1640 Agar w/MOPS and 2% Glucose 62

Oxoid Launches Rapid MDG Broth 62

Lonza Introduces microCompass TYMC (Total Yeast and Mould

Count) Detection Kit 63

Inverness Medical Introduces Determine HIV-1/2 Ag/Ab Combo 63

Meridian Bioscience Rolls Out Two New Rapid Tests for

Detecting Epstein-Barr Virus 64

Oxoid Introduces Staph Plus System for Identifying

Staphylococcal Species 64

8. PRODUCT INNOVATIONS/INTRODUCTIONS IN RECENT PAST - A

PERSPECTIVE BUILDER 65

Siemens Healthcare Diagnostics Launches MicroScan® WalkAway®

plus Diagnostic Microbiology Systems 65

Bio-Rad Launches a Rapid test for Screening MRSA, MRSASelect™

test, in US 65

bioMerieux Introduces VIDAS®, an automated Clostridium

difficile A & B Toxins Detection Test 65

Oxoid Launches Remel Wellcolex® Colour Tests for Testing

Shigella, E. coli O157 and Salmonella 66

Siemens Healthcare Diagnostics Obtains Health Canada Approval

for its VERSANT 440 Molecular System 66

Oxoid Unveils Remel Xpect™ Clostridium Difficile Toxin A/B Test 66

Neogen Introduces Soleris System 66

ATCC Introduces Authenticult™ Quality Control Microbiological

Testing Tool 67

Bio-Rad Introduces New EBV Kits 67

Roche Seeks FDA Marketing Approval for Hepatitis C Virus Test 67

Roche Seeks US FDA Approval for its Cobas TaqScreen MPX Test 67

FDA Clears Usage of TIGRIS® System for Testing WNV in Donated

Blood 68

FDA Approves ImmunoCard STAT!® EHEC for Detecting E. coli

Infection 68

bioMerieux Introduces TEMPO® Quality Indicator Testing System 68

Biotrace Introduces Tecra Unique Campylobacter Rapid Test 68

bioMerieux Introduces TEMPO® EB test for Enterobacteriaceae 69

Roche Unveils Elecsys TORCH Assays 69

Roche Diagnostics Introduces Cobas TaqMan MTB Test in Japan 69

bioMerieux Develops Advanced Colorimetry™ NH Card 69

Roche Introduces Rapid LightCycler SeptiFast Sepsis Test

across EU 69

Oxoid Launches New Rapid Test for Salmonella Detection in Food

Products 70

Oxoid Unveils New Contact Plate Design 70

FDA Approves Fluconazole Susceptibility Tests from BioMerieux 70

Polysciences Unveils New Microbiological & Bacterial Detection

Applications 70

Researchers Develop New Rapid MODS Test for TB Detection 71

Dade Behring Unveils Automated Quadriga BeFree System 71

FDA Approves Abbott PRISM® HBsAg Assay 71

Bayer's EHIV Test Receives FDA Clearance 72

Gen-Probe Obtains FDA Approval to Use Aptima Test on

Additional Specimens 72

Roche Diagnostics' cobas TaqScreen MPX Test Receives CE Mark

Approval 72

Cepheid Introduces Rapid Xpert® MRSA Test in Europe 72

Bio-Rad Widens Culture Media with Addition of RAPID'Salmonella 73

Chemogen Develops New Tuberculosis Rapid Test 73

bioMerieux Rolls Out VIDAS® LDUO Test 73

Zonda Develops New Rapid Test for Chlamydia 73

MedMira Launches MiraCare Rapid HIV Test 73

STMicroelectronics and Mobidiag Unveil Lab-On-Chip 73

Vermicon Launches ScanVIT-Legionella Rapid Test Kit 74

New Line of Rapid Microbial Detection Systems from Centrus 74

OraSure Rolls Out OraQuick ADVANCE 74

Abbott Unveils Automated HCV Test 74

ViroMed Rolls Out Rapid PCR Tests for Detecting Influenza and

Respiratory Pathogens 74

Biophage Pharma Offers Service for Microbiological Testing 75

bioMerieux Releases New Rapid Test for Nosocomial Infections 75

bioMerieux Widens Product Portfolio with Addition of TEMPO®

System 75

9. RECENT INDUSTRY ACTIVITY 76

Inverness Medical Adopts New Corporate Identity 76

Thermo Fisher Acquires Ahura Scientific 76

Don Whitley Signs Distribution Agreement with Zisys 76

Charm Sciences Acquires MLX Microplate Luminometer Product

Line from Dynex Technologies 77

Alpha Analytical Acquires Boston Analytical Inc. 77

Roche Group Acquires Genentech 77

Roche Acquires Innovatis AG 78

3M Takes Over Biotrace International 78

Lab21 Buys Majority Stake in Biotec Laboratories 78

Vacci-Test Acquires Maxivet 79

bioMerieux Acquires PML Microbiologicals 79

3M Acquires Food Diagnostics AS 79

Becton, Dickinson and Company Receives License for its

GeneOhmTM from Health Canada 80

BD Diagnostics Receives CE Marking for BD GeneOhmTM VanR Test 80

bioMerieux Bags AOAC Research Institute's Performance- Tested

Methods SM Approval 80

MedMira Receives Sales Approval of Multiplo HBV/HIV/HCV Rapid

Tests Market 80

Schering-Plough Inks International Collaboration Agreement

with OraSure Technologies 81

Roche Selects Quidel's Influenza Test 81

Quidel Enters into Global Alliance with bioMerieux 82

Premier's QUEST Selects Remel SpectraTM MRSA 82

Thermo Fisher Scientific and MedAssets Supply Chain Systems

Enter into a Supply Agreement 82

Thermo Fisher Scientific Bags FDA Approval for SpectraTM MRSA 82

Advantest to Take Over Credence Systems 83

DSM Food Specialties to Acquire CMT Srl 83

Sysmex Signs Agreement with bioMerieux 83

Nanogen Enters into Definitive Agreement with Elitech Group 84

Silliker Acquires Majority Stake in EGI Laboratory 84

BD Establishes New Rapid Diagnostic Products Manufacturing

Facility in China 84

Quidel Corporation Obtains CLIA Waiver from US FDA for its

QuickVue(R) RSV Test 84

Siemens Obtains US FDA Approval for its VERSANT™ 440 Molecular

System 85

bioMerieux to Market Wescor's Customized Slide Stainer

Instruments under bioMerieux Brand 85

Schering-Plough and OraSure Ink Collaboration Agreement for

Developing Rapid Oral HCV Test 85

Abbott Obtains US FDA Approval for its Automated HTLV-I/HTLV-

II Blood Screening Test 86

Quidel and bioMerieux Form a Long-term Alliance in Rapid

Diagnostic Tests 86

BD Diagnostics Obtains US FDA Approval for BD GeneOhm™ StaphSR

Assay 86

10. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER 87

Siemens Acquires Dade Behring 87

Concateno Acquires Euromed 87

Meridian Bioscience Obtains US FDA Approval for Two New Rapid

Tests 87

Thermo Fisher Scientific Teams Up with KBA for Expanding its

Microbiology Business Division in Lenexa 87

OraSure and SCMS Enter into an Agreement for Supplying

OraQuick(R) HIV Test to PEPFAR Countries 88

Abbott Obtains US FDA Approval for its Fully Automated PRISM®

HCV Test 88

Gen-Probe Obtains US FDA Approval for its PROCLEIX® TIGRIS®

System for Testing Donated Blood 88

AdvanDx Ropes In bioMerieux for Distributing its Rapid

Diagnostic Tests in US 88

3M and Gen-Probe Join Hands to Develop Rapid Molecular Tests

For Detecting HAIs 89

Gen-Probe's PROCLEIX® TIGRIS® System Obtains US FDA Approval

for Screening Donated Blood for West Nile Virus 89

3M Acquires Acolyte Biomedica 89

Formation of Siemens Medical Solutions Diagnostics 90

bioMerieux Bags Contract to Provide VITEK® 2 System for

Scottish NHS Labs 90

bioMerieux Licenses NorChip's HPV Test Technology for Cervical

Cancer 91

bioMerieux in Strategic Agreement with Cepheid for Sepsis Assays 91

3M Health Care Creates New Medical Diagnostics Unit 91

Schering-Plough & OraSure to Develop Rapid Oral HCV Test 92

3M Acquires Biotrace International 92

Siemens Acquires DPC 92

Oxoid Acquires Microbiology Business Activities of Dako 93

Inverness Acquires IDT and Thermo BioStar 93

BMD in Agreement with MND for Research on Diagnostic Tests 93

Cepheid Wins CDC Contract to Develop Rapid Bird Flu Virus

Detection Test 93

Dutch Government Grants €7.9 Million to FIND 94

FIND and Hain to Develop Rapid Test for MDR and XDR TB 94

3M & Gen-Probe Ally for Developing Rapid Molecular Tests for

Food Safety 94

Bio View Inks Three-Year Distribution Agreement with Abbott

Molecular 95

Bodycote Acquires Foodscan Laboratories 95

Cepheid Bags STTR Funding for Development of Rapid TB Test 95

Abbott and Verax in Distribution Agreement for Verax Platelet

PGD® Test 96

BSL Supplies ABBOTT PRISM® System to Blood Donor Testing Centers 96

Abbott & ARC in Agreement for Automated Blood Screening Tests 96

BD to Set Up Production Facility for Rapid Diagnostic Products

in China 97

BD Diagnostics Delivers STI Testing Products to BioReference 97

Meridian Licenses LAMP Diagnostic Test Technology from Eiken 97

OraSure Inks Multi-Year Purchase Contract with New York City 97

Abbott Inks Single-Source Agreement with Novation for HIV Test 98

Neogen Takes Over Centrus International 98

Becton, Dickinson and Company Acquires GeneOhm Sciences 98

Inverness Medical Innovations Makes a Synergetic Purchase of

ACON Laboratories 98

Quest Diagnostics Strikes Deal with BD Diagnostics 99

Novation Inks Pact with Abbott for Rapid HIV-1/2 Antibody Test 99

TREK Diagnostic and Novation Inks Agreement 99

Clinton Foundation Inks Agreement with Four Companies to Cut

Prices 99

Chembio Obtains FDA Approval for HIV 1/2 Stat-Pak and Sure

Check HIV 1/2 Rapid Test PMAs 99

Roche's LightCycler SeptiFast Test Attains CE Mark 100

Zonda Expands Distribution of Products in Europe 100

OraSure Wins Rapid HIV Tests Order 100

MedMira Secures Orders for Rapid HIV Tests 100

Cepheid Collaborates with Foundation for Innovative Diagnostics 100

Chembio Obtains Clearance for Rapid HIV Tests in Kenya 101

Genesis Bioventures Bags US Patent for Rapid Prion- Detection

Assay 101

MedMira Obtains CE Mark for MiraCare 101

Setema to Distribute Chembio's Rapid HIV Tests in Ethiopia 101

Clinton Foundation HIV/AIDS Initiative Selects Chembio to

Provide Rapid HIV Tests 101

Quidel Acquires immunochemical Fecal Occult Blood Test 101

Xact Aid Snaps Up STD Alert 102

Grant Life Sciences Acquires Rapid Tests from AccuDx 102

Millipore Ties Up with Gen-Probe 102

Foundation for Innovative New Diagnostics forms Collaboration

with Eiken Chemical 102

WayPoint and Global Rapid Diagnostic Leader Enter into an

Agreement 102

Akers Biosciences Enters into a Distribution Agreement with

Alco Industries 103

Celsis and BioVentures Enter into Licensing Agreement 103

Thermo Electron Inks Pact with Genomic Profiling Systems 103

Abbott and OraSure Enters into Agreement for OraQuick ADVANCE

Rapid HIV-1/2 Test 103

bioMerieux Signs Agreement with Novel Diagnostics 103

Dade Behring Bags FDA Approval for Antimicrobial

Susceptibility Test Panels 103

OraSure Bags HCV Patent License from Chiron and Ortho-

Clinical Diagnostics 104

BD Diagnostics Receives FDA Approval for BD Directigen™ EZ Flu

A+B Test 104

BD Diagnostics Bags FDA Clearance for BBL™ CHROMagar™ MRSA

Product 104

MedMira Obtains Rights to Market Rapid HIV Tests in Guizhou

Province, China 104

Gen-Probe Obtains FDA Clearance for PROCLEIX® West Nile Virus

Assay 104

Medical Services International Secures Clearance for Rapid

Test Kits 104

Medical Services International Receives Exclusive Marketing

Rights for TB Test Kit 105

Adaltis Receives Orders for HIV Rapid Tests from China 105

MedCap Bags Exclusive Distribution Rights for Syphilis Rapid Test 105

Genomic Profiling Systems Obtains NIAID Funds to Develop

Testing Platform 105

Gen-Probe Obtains US Patent for Automated Process for Nucleic

Acid Testing 105

Bio-Rad Receives Approval for HIV-1/HIV-2 Rapid Test 105

11. FOCUS ON SELECT GLOBAL PLAYERS 106

Abbott Laboratories (USA) 106

Abbott Diagnostics (USA) 106

Alere Inc. (US) 106

Becton Dickinson and Company (USA) 107

bioMerieux SA (France) 107

bioMerieux, Inc. (USA) 108

Bio-Rad Laboratories, Inc (USA) 108

Cellabs Pty Ltd (Australia) 108

Celsis International Plc (UK) 109

Coris BioConcept (Belgium) 109

F. Hoffmann-La Roche Ltd. (Switzerland) 109

Gen-Probe Inc. (USA) 110

Genzyme Diagnostics (USA) 110

MedMira, Inc. (Canada) 111

Meridian Biosciences, Inc. (USA) 111

Orasure Technologies, Inc. (USA) 111

Orion Diagnostica Oy (Finland) 112

Quidel Corp. (USA) 112

Siemens Healthcare Diagnostics, Inc. (USA) 113

Thermo Fisher Scientific, Inc. (USA) 113

Remel, Inc. (USA) 113

Oxoid Limited (UK) 114

12. GLOBAL MARKET PERSPECTIVE 115

Table 7: World Recent Past, Current & Future Analysis for

Automated and Rapid Microbiological Tests by Geographic Region-

US, Europe, and Rest of World Independently Analyzed with

Annual Revenues in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 115

Table 8: World Historic Review for Automated and Rapid

Microbiological Tests by Geographic Region - US, Europe, and

Rest of World Independently Analyzed with Annual Revenues in

US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 116

Table 9: World 10-Year Perspective for Automated and Rapid

Microbiological Tests by Geographic Region - Percentage

Breakdown of Revenues for US, Europe, and Rest of World for

Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 117

Table 10: World Recent Past, Current & Future Analysis for

Automated and Rapid Microbiological Tests in Clinical

Applications by Geographic Region - US, Europe, and Rest of

World Independently Analyzed with Annual Revenues in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 118

Table 11:World Historic Review for Automated and Rapid

Microbiological Tests in Clinical Applications by Geographic

Region - US, Europe, and Rest of World Independently Analyzed

with Annual Revenues in US$ Million for Years 2000 through

2006 (includes corresponding Graph/Chart) 119

Table 12: World 10-Year Perspective for Automated and Rapid

Microbiological Tests in Clinical Applications by Geographic

Region - Percentage Breakdown of Revenues for US, Europe, and

Rest of World for Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 120

Table 13: World Recent Past, Current & Future Analysis for

Automated and Rapid Microbiological Tests in Clinical

Applications by Equipment Used - Automated Identification &

Susceptibility Systems, Automated Blood Culture Systems,

Automated Tuberculosis Systems, Streptococcal Infection Rapid

Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid

Microbiological Tests Independently Analyzed with Annual

Revenues in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 121

Table 14: World Historic Review for Automated and Rapid

Microbiological Tests in Clinical Applications by Equipment

Used - Automated Identification & Susceptibility Systems,

Automated Blood Culture Systems, Automated Tuberculosis

Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia

Rapid Tests and Other Automated & Rapid Microbiological Tests

Independently Analyzed with Annual Revenues in US$ Million for

Years 2000 through 2006 (includes corresponding Graph/Chart) 122

Table 15: World 10-Year Perspective for Automated and Rapid

Microbiological Tests in Clinical Applications by Equipment

Used - Percentage Breakdown of Revenues for Automated

Identification & Susceptibility Systems, Automated Blood

Culture Systems, Automated Tuberculosis Systems, Streptococcal

Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other

Automated & Rapid Microbiological Tests for Years 2005,2010 &

2015 (includes corresponding Graph/Chart) 123

Table 16: World Recent Past, Current & Future Analysis for

Automated Identification & Susceptibility Systems in Clinical

Applications by Geographic Region - US, Europe, and Rest of

World Independently Analyzed with Annual Revenues in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 124

Table 17: World Historic Review for Automated Identification &

Susceptibility Systems in Clinical Applications by Geographic

Region - US, Europe, and Rest of World Independently Analyzed

with Annual Revenues in US$ Million for Years 2000 through

2006 (includes corresponding Graph/Chart) 125

Table 18: World 10-Year Perspective for Automated

Identification & Susceptibility Systems in Clinical

Applications by Geographic Region - Percentage Breakdown of

Revenues for US, Europe, and Rest of World for Years 2005,

2010 & 2015 (includes corresponding Graph/Chart) 126

Table 19: World Recent Past, Current & Future Analysis for

Automated Blood Culture Systems in Clinical Applications by

Geographic Region - US, Europe, and Rest of World

Independently Analyzed with Annual Revenues in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 127

Table 20: World Historic Review for Automated Blood Culture

Systems in Clinical Applications by Geographic Region - US,

Europe, and Rest of World Independently Analyzed with Annual

Revenues in US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 128

Table 21: World 10-Year Perspective for Automated Blood

Culture Systems in Clinical Applications by Geographic Region

- Percentage Breakdown of Revenues for US, Europe, and Rest of

World for Years 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 129

Table 22: World Recent Past, Current & Future Analysis for

Automated Tuberculosis Systems in Clinical Applications by

Geographic Region - US, Europe, and Rest of World

Independently Analyzed with Annual Revenues in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 130

Table 23: World Historic Review for Automated Tuberculosis

Systems in Clinical Applications by Geographic Region - US,

Europe, and Rest of World Independently Analyzed with Annual

Revenues in US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 131

Table 24: World 10-Year Perspective for Automated Tuberculosis

Systems in Clinical Applications by Geographic Region -

Percentage Breakdown of Revenues for US, Europe, and Rest of

World for Years 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 132

Table 25: World Recent Past, Current & Future Analysis for

Streptococcal Infection Rapid Tests in Clinical Applications

by Geographic Region - US, Europe, and Rest of World

Independently Analyzed with Annual Revenues in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 133

Table 26: World Historic Review for Streptococcal Infection

Rapid Tests in Clinical Applications by Geographic Region -

US, Europe, and Rest of World Independently Analyzed with

Annual Revenues in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 134

Table 27: World 10-Year Perspective for Streptococcal

Infection Rapid Tests in Clinical Applications by Geographic

Region - Percentage Breakdown of Revenues for US, Europe, and

Rest of World for Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 135

Table 28: World Recent Past, Current & Future Analysis for

GC/Chlamydia Rapid Tests in Clinical Applications by

Geographic Region - US, Europe, and Rest of World

Independently Analyzed with Annual Revenues in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 136

Table 29: World Historic Review for GC/Chlamydia Rapid Tests

(*) in Clinical Applications by Geographic Region - US,

Europe, and Rest of World Independently Analyzed with Annual

Revenues in US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 137

Table 30: World 10-Year Perspective for GC/Chlamydia Rapid

Tests in Clinical Applications by Geographic Region -

Percentage Breakdown of Revenues for US, Europe, and Rest of

World for Years 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 138

Table 31: World Recent Past, Current & Future Analysis for

Other Automated & Rapid Microbiological Tests in Clinical

Applications by Geographic Region - US, Europe, and Rest of

World Independently Analyzed with Annual Revenues in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 139

Table 32: World Historic Review for Other Automated & Rapid

Microbiological Tests in Clinical Applications by Geographic

Region - US, Europe, and Rest of World Independently Analyzed

with Annual Revenues in US$ Million for Years 2000 through

2006 (includes corresponding Graph/Chart) 140

Table 33: World 10-Year Perspective for Other Automated &

Rapid Microbiological Tests in Clinical Applications by

Geographic Region - Percentage Breakdown of Revenues for US,

Europe, and Rest of World for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 141

Table 34: World Recent Past, Current & Future Analysis for

Automated and Rapid Microbiological Tests in Non-Clinical

Applications by Geographic Region - US, Europe, and Rest of

World Independently Analyzed with Annual Revenues in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 142

Table 35: World Historic Review for Automated and Rapid

Microbiological Tests in Non-Clinical Applications by

Geographic Region - US, Europe, and Rest of World

Independently Analyzed with Annual Revenues in US$ Million for

Years 2000 through 2006 (includes corresponding Graph/Chart) 143

Table 36: World 10-Year Perspective for Automated and Rapid

Microbiological Tests in Non-Clinical Applications by

Geographic Region - Percentage Breakdown of Revenues for US,

Europe, and Rest of World for Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 144

13. THE UNITED STATES 145

A.Market Analysis 145

A Current & Future Analysis 145

Rapid Microbiology Tests - A Competitive Profile 145

Consolidation in the Automated and Rapid Microbiological

Tests Market 145

Bioterrorism Tests - Gaining Prominence 146

Tracking Trends Across Product Segments 146

STD Rapid Tests 146

Market Share Trends of Leading Players in the Recent Past 146

Table 37: Leading Players in the US Market for

GC/Chlamydia Rapid Tests (2004 & 2005) - Percentage

Breakdown of Value Sales by Company for Gen-Probe, Abbott,

Becton Dickinson and Roche (includes corresponding

Graph/Chart) 147

Table 38: Leading Players in the US Market for Chlamydia

Rapid Tests (2004 & 2005) - Percentage Breakdown of Value

Sales by Company for Thermo Electron, Wampole / Inverness

Medical Innovations, and Quidel (includes corresponding

Graph/Chart) 147

Table 39: Leading Players in the US Market for Syphilis

Rapid Tests (2004 & 2005) - Percentage Breakdown of Value

Sales by Company for Becton Dickinson, Wampole/Inverness

Medical Innovations, and Others (includes corresponding

Graph/Chart) 148

Leading Players in HIV Rapid Testing Market 148

Gastrointestinal Rapid Tests 148

Market Share Data of Leading Players in the Recent Past 149

Table 40: Leading Players in the US Market for C.

Difficile Rapid Tests (2004 & 2005) -Percentage Breakdown

of Value Sales by Company for Wampole/Inverness Medical

Innovations, Meridian Biosciences, BioSite, Becton

Dickinson, Thermo Electron, and Others (includes

corresponding Graph/Chart) 149

Table 41: Leading Players in the US Market for

Cryptosporidium Rapid Tests (2004 & 2005) - Percentage

Breakdown of Value Sales by Company for Remel, Meridian

Biosciences, and Becton Dickinson (includes

correspondingGraph/Chart) 149

Table 42: Leading Players in the US Market for Rotavirus

Rapid Tests (2004 & 2005) - Percentage Breakdown of Value

Sales by Company for Meridian Biosciences,

FisherScientific, and Others (includes corresponding

Graph/Chart) 150

Table 43: Leading Players in the US Market for Giardia

Rapid Tests (2004 & 2005) - Percentage Breakdown of Value

Sales by Company for Remel, Meridian Biosciences, and

Becton Dickinson (includes corresponding Graph/Chart) 150

Respiratory Rapid Tests 150

Competition 151

Market Share Data of Leading Players in the Recent Past 151

Table 44: Leading Players in the US Market for Influenza

Rapid Tests (2004 & 2005) - Percentage Breakdown of

Value Sales by Company for Quidel, Becton Dickinson,

Thermo Electron, Binax and Others (includes

corresponding Graph/Chart) 151

Table 45: Leading Players in the US Market for RSV Rapid

Tests (2004 & 2005) - Percentage Breakdown of Value

Sales by Company for Becton Dickinson, Binax,Thermo

Electron and Others (includes corresponding Graph/Chart) 152

Table 46: Leading Players in the US Market for

Tuberculosis Rapid Tests (2004 & 2005) - Percentage

Breakdown of Value Sales by Company for Gen-Probe, and

Becton Dickinson 152

Table 47: Leading Players in the US Market for M.

Pneumoniae Rapid Tests (2004 & 2005) - Percentage

Breakdown of Value Sales by Company for Meridian

Biosciences, and Remel, Inc. 152

Table 48: Leading Players in the US Market for

Mononucleosis Rapid Tests (2004 & 2005) - Percentage

Breakdown of Value Sales by Company for Wampole, Remel,

Quidel, Thermo Electronand Others (includes

corresponding Graph/Chart) 153

Streptococcus Infection Rapid Tests 153

Market Share Data of Leading Players in the Recent Past 154

Table 49: Leading Players in the US Market for

Streptococcus A Rapid Tests (2004 & 2005) -Percentage

Breakdown of Value Sales by Company for Quidel, Thermo

Electron, Becton Dickinson, Genzyme and Others (includes

corresponding Graph/Chart) 154

A Peek into the Testing Practices of the US Food Industry 154

B.Market Analytics 155

Table 50: US Recent Past, Current & Future Analysis for

Automated & Rapid Microbiological Tests by End-Use Segment -

Clinical Applications (Automated Identification &

Susceptibility Systems, Automated Blood Culture Systems,

Automated Tuberculosis Systems, Streptococcal Infection

Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &

Rapid Microbiological Tests) and Non- Clinical Applications

Independently Analyzed with Annual Revenues in US$ Million

for Years 2007 through 2015 (includes corresponding

Graph/Chart) 155

Table 51: US Historic Review for Automated & Rapid

Microbiological Tests by End-Use Segment - Clinical

Applications (Automated Identification& Susceptibility

Systems, Automated Blood Culture Systems, Automated

Tuberculosis Systems, Streptococcal Infection Rapid Tests,

GC/Chlamydia Rapid Tests, and Other Automated & Rapid

Microbiological Tests) and Non-Clinical Applications

Independently Analyzed with Annual Revenues in US$ Million

for Years 2000 through 2006 (includes corresponding

Graph/Chart) 156

Table 52: US 10-Year Perspective for Automated & Rapid

Microbiological Tests by End-Use Segment - Percentage

Breakdown of Revenues for Clinical Applications (Automated

Identification & Susceptibility Systems, Automated Blood

Culture Systems, Automated Tuberculosis Systems,

Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid

Tests, and Other Automated & Rapid Microbiological Tests)

and Non-Clinical Applications for 2005, 2010 & 2015

(includes corresponding Graph/Chart) 157

Table 53: US Recent Past, Current & Future Analysis for

Rapid Microbiological Tests by End-Use Segment - Clinical

Applications (Streptococcus Infection Rapid Tests

{Streptococcus A, and Streptococcus B}, STD Rapid Tests

{GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests

{RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae,

Legionella, and Influenza} and Gastrointestinal Rapid Tests

{Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H.

Pylori}) and Non-Clinical Applications Independently

Analyzed with Annual Revenues in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 158

Table 54: US Historic Review for Rapid Microbiological Tests

by End-Use Segment - Clinical Applications (Streptococcus

Infection Rapid Tests {Streptococcus A, and Streptococcus

B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis},

Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis,

Mycoplasma Pneumoniae, Legionella, and Influenza} and

Gastrointestinal Rapid Tests {Cryptosporidium, Giardia,

Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical

Applications Independently Analyzed with Annual Revenues in

US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 159

Table 55: US 10-Year Perspective for Rapid Microbiological

Tests by End-Use Segment - Percentage Breakdown of Revenues

for Clinical Applications (Streptococcus Infection Rapid

Tests {Streptococcus A, and Streptococcus B}, STD Rapid

Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid

Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma

Pneumoniae, Legionella, and Influenza} and Gastrointestinal

Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C.

Difficile, and H. Pylori}) and Non-Clinical Applications for

2005, 2010 & 2015 (includes corresponding Graph/Chart) 160

14. EUROPE 161

A.Market Analysis 161

A Current & Future Analysis 161

European Market Primer 161

What Drives the Requirement Patterns of End-Users? 161

Trends & Issues 162

Proliferation of Automated, and Rapid Tests in Europe 162

European Automated Market 163

Probe Tests: "A Crack in the Future of Rapid Tests" 163

Trends Across Product Segments 163

GC/Chlamydia Rapid Tests 163

Streptococcal Infection (Strep A) Rapid Tests 163

Automated Tuberculosis Systems Market 164

Market Share Data of Leading Players - A Historic Perspective 164

Table 56: Leading Players in European Market for Automated

& Rapid Microbiological Tests (2000) - Percentage Breakdown

of Value Sales by Company for bioMerieux, Becton Dickinson,

Organon Teknika, Merlin, Abbott, Dade, Unipath, and Others

(includes corresponding Graph/Chart) 164

Table 57: Leading Players in European Market for Chlamydia

Rapid Tests (2000) - Percentage Breakdown of Value Sales by

Company for Abbott, Oxoid, Unipath, Quidel, and Others

(includes corresponding Graph/Chart) 164

Table 58: Leading Players in European Market for

Streptococcal Infection (Strep A) Rapid Tests (2000) -

Percentage Breakdown of Value Sales by Company for Abbott,

Unipath, Quidel, Orion Diagnostics, Oxoid, and Becton

Dickinson (includes corresponding Graph/Chart) 165

B.Market Analytics 165

Table 59: European Recent Past, Current & Future Analysis

for Automated & Rapid Microbiological Tests by Geographic

Region - France, Germany, The United Kingdom, Italy, Spain,

Russia, & Rest of Europe Independently Analyzed with Annual

Revenues in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) 165

Table 60: European Historic Review for Automated & Rapid

Microbiological Tests by Geographic Region - France,

Germany, The United Kingdom, Italy, Spain, Russia, & Rest of

Europe Independently Analyzed with Annual Revenues in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 166

Table 61: European 10-Year Perspective for Automated & Rapid

Microbiological Tests by Geographic Region - Percentage

Breakdown of Revenues for France, Germany, The United

Kingdom, Italy, Spain, Russia, & Rest of Europe for Years

2005, 2010 & 2015 (includes corresponding Graph/Chart) 167

Table 62: European Recent Past, Current & Future Analysis

for Automated & Rapid Microbiological Tests by End-Use

Segment - Clinical Applications (Automated Identification &

Susceptibility Systems, Automated Blood Culture Systems,

Automated Tuberculosis Systems, Streptococcal Infection

Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &

Rapid Microbiological Tests) and Non-Clinical Applications

Independently Analyzed with Annual Revenues in US$ Million

for Years 2007 through 2015 (includes corresponding

Graph/Chart) 168

Table 63: European Historic Review for Automated & Rapid

Microbiological Tests by End-Use Segment - Clinical

Applications (Automated Identification & Susceptibility

Systems, Automated Blood Culture Systems, Automated

Tuberculosis Systems, Streptococcal Infection Rapid Tests,

GC/Chlamydia Rapid Tests, and Other Automated & Rapid

Microbiological Tests) and Non-Clinical Applications

Independently Analyzed with Annual Revenues in US$ Million

for Years 2000 through 2006 (includes corresponding

Graph/Chart) 169

Table 64: European 10-Year Perspective for Automated & Rapid

Microbiological Tests by End-Use Segment - Percentage

Breakdown of Revenues for Clinical Applications (Automated

Identification & Susceptibility Systems, Automated Blood

Culture Systems, Automated Tuberculosis Systems,

Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid

Tests, and Other Automated & Rapid Microbiological Tests)

and Non-Clinical Applications for 2005, 2010 & 2015

(includes corresponding Graph/Chart) 170

14a. FRANCE 171

A.Market Analysis 171

A Current & Future Analysis 171

bioMerieux: A Key Player 171

Market Share Data of Leading Players - A Historic Perspective 172

Table 65: Leading Players in French Market for Automated &

Rapid Microbiological Tests (2000) - Percentage Breakdown

of Value Sales by Company for bioMerieux, Becton

Dickinson, Merlin, Organon Teknika, Dade, Pasteur Sanofi

Diagnostic, Oxoid and Abbott (includes corresponding

Graph/Chart) 172

To order this report:

Diagnostics Industry: Global Automated And Rapid Microbiological Tests Industry

More  Market Research Report

Check our  Real Time Industry Data

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response
2. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
3. Forward step in forecasting global warming
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
5. Bionovo to Present at Canaccord Adams Global Growth Conference
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
8. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
9. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
10. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
11. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal Inc., ... proprietary NeXosome® technology for early warning of adverse ... most recent study by Dr. Thomas McElrath ... Society for Maternal Fetal Medicine,s (SMFM) annual meeting held ... th , 2016.  The presentation reported initial positive ...
(Date:2/10/2016)... Feb. 10, 2016  IsoRay, Inc. (NYSE MKT: ISR), ... and medical radioisotope applications for the treatment of prostate, ... announced its financial results for the second quarter and ... 2015. --> --> ... of fiscal 2016, which ended December 31, 2015, a ...
(Date:2/10/2016)... Texas (PRWEB) , ... February 10, 2016 , ... ... centers across three states, announced today the promotion of two long-standing principal investigators ... Chief of Family Medicine, Clinical Research and Development. , Dr. Laurence Chu, a ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... their comprehensive training and support program, Sonalinkā„¢ remote monitoring. The inaugural launch of ... on Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU technical expert ...
Breaking Biology Technology:
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/18/2016)... Jan. 18, 2016  Extenua Inc., a pioneering ... the use and access of ubiquitous on-premise and ... with American Cyber.  ... leading transformational C4ISR and Cyber initiatives in support ... latest proven technology solutions," said Steve Visconti ...
Breaking Biology News(10 mins):